Imfinzi
AstraZeneca’s Imfinzi approved in US for endometrial cancer treatment
June 17, 2024Medical Communications AstraZeneca, Imfinzi, Oncology, chemotherapy, endometrial cancer
AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Imfinzi (durvalumab) in combination with carboplatin and …
AstraZeneca shares results for Imfinzi in phase 3 trial for small cell lung cancer
April 5, 2024Research and Development AstraZeneca, Imfinzi, Oncology, clinical trial, lung cancer
AstraZeneca has announced positive high-level results from the phase 3 ADRIATIC trial, which demonstrated that Imfinzi (durvalumab) had a statistically …
AstraZeneca’s Imfinzi meets primary endpoint for liver cancer treatment
November 13, 2023Research and Development AstraZeneca, Imfinzi, Oncology, clinical trial, liver cancer
AstraZeneca has announced positive results from the EMERALD-1 phase 3 trial for Imfinzi (durvalumab) in combination with transarterial chemoembolisation (TACE) …
AstraZeneca to withdraw Imfinzi US indication for bladder cancer
February 22, 2021Sales and Marketing AstraZeneca, Imfinzi
AstraZeneca will voluntarily withdraw the Imfinzi (durvalumab) indication in the US for previously treated adult patients with locally advanced or …
AstraZeneca’s Imfinzi gets EU and UK approval for new dosing option
January 15, 2021Medical Communications AstraZeneca, Cancer, Imfinzi
AstraZeneca’s Imfinzi (durvalumab) has been approved in the EU and the UK for an additional dosing option in locally advanced, …
EMA panel recommends label extension of AstraZeneca’s Imfinzi in non-small cell lung cancer
December 15, 2020Manufacturing and Production, Sales and Marketing AstraZeneca, Europe, Imfinzi, NSCLC
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has backed a new dosing regimen of AstraZeneca’s …
AstraZeneca scores Japanese approval for Imfinzi combo in extensive-stage small cell lung cancer
August 21, 2020Medical Communications, Sales and Marketing AstraZeneca, Imfinzi, Japan
AstraZeneca’s Imfinzi (durvalumab) has secured approval in Japan for the treatment of extensive-stage small cell lung cancer when combined with etoposide and …
Two CHMP recommendations for AstraZeneca: Imfinzi in first-line lung cancer, Calquence in chronic lymphocytic leukaemia
July 27, 2020Sales and Marketing AstraZeneca, CHMP, Calquence, EMA, Imfinzi
AstraZeneca has secured two new recommendations for approval of its products from the European Medicines Agency’s Committee for Medicinal Products …
FDA immunotherapy first with the approval of AZ’s Imfinzi in first-line extensive-stage small cell lung cancer
March 30, 2020Sales and Marketing AstraZeneca, Cancer, FDA, Imfinzi, lung cancer, pharma
AstraZeneca has seized FDA approval for its immune checkpoint inhibitor Imfinzi (durvalumab) in the first-line treatment of extensive-stage small cell …
Success and failure at Phase 3 for AstraZeneca’s Imfinzi combos in first-line small cell lung cancer
March 17, 2020Manufacturing and Production, Research and Development AstraZeneca, Cancer, Imfinzi, pharma
AstraZeneca has pulled back the curtain on new Phase 3 data for Imfinzi (durvalumab) in the first-line treatment of extensive-stage …
Phase 3 failure for AstraZeneca’s Imfinzi combo in unresectable metastatic bladder cancer
March 6, 2020Medical Communications, Research and Development AstraZeneca, Cancer, Imfinzi, bladder cancer, pharma, trial failure
New Phase 3 has been released by AstraZeneca, showing that the PD-L1 inhibitor Imfinzi (durvalumab), when combined with tremelimumab, failed …
China approves AstraZeneca’s Imfinzi for advanced non-small cell lung cancer
December 12, 2019Sales and Marketing AstraZeneca, Imfinzi, pharma
AstraZeneca’s Imfinzi (durvalumab) is set to be made available in China after the country’s National Medical Products Administration (NMPA) decided …
FDA gives priority review for AstraZeneca’s Imfinzi
November 29, 2019Medical Communications AstraZeneca, Cancer, FDA, Imfinzi, lung cancer
The FDA has granted a priority review of AstraZeneca’s cancer treatment drug Imfinzi (durvalumab) for treatment of patients with untreated …
AstraZeneca’s Imfinzi triple combo beats chemo in treatment-naive metastatic lung cancer
October 29, 2019Manufacturing and Production, Research and Development AstraZeneca, Cancer, Imfinzi, NSCLC, lung cancer, pharma
AstraZeneca has unveiled positive new Phase 3 data for the combination of Imfinzi (durvalumab) and anti-CTLA4 antibody tremelimumab with chemotherapy …
AstraZeneca’s Imfinzi combo tops chemotherapy in treatment-naive advanced lung cancer
September 9, 2019Sales and Marketing AstraZeneca, Cancer, Imfinzi, lung cancer, pharma
AstraZeneca has unveiled new Phase 3 data for its immunotherapy Imfinzi (durvalumab), showing that it achieved its primary endpoint when …
